In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Validation of the Barrow Neurological Institute Scale for Symptomatic Vasospasm Prediction Following Aneurysmal Subarachnoid Hemorrhage

    Final Number:
    302

    Authors:
    Christopher James Stapleton MD; Brian Patrick Walcott MD; Seunggu Jude Han MD; Matthew J Koch MD; Arjun Khanna MD; Christopher S. Ogilvy MD; Aman B. Patel MD; Michael T. Lawton MD

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2017 Annual Meeting

    Introduction: The Barrow Neurological Institute (BNI) scale (Table) was introduced in 2012 as a simple and quantitative method for symptomatic vasospasm prediction following aneurysmal subarachnoid hemorrhage (SAH). The scale was developed from data collected from 218 patients from the Barrow Ruptured Aneurysm Trial (BRAT). Validation of this scale in a large, multicenter aneurysmal SAH cohort may encourage its use in broader clinical neurovascular practice.

    Methods: The records of 474 patients with aneurysmal SAH were studied to evaluate the predictive capacities of the BNI and original Fisher scales. The study sample included 241 patients from Massachusetts General Hospital (MGH) and 233 patients from the University of California, San Francisco (UCSF).

    Results: Within this external cohort, the mean age at the time of presentation was 55.7 years and there were 353 (74.5%) female patients. Of the 474 total patients, 108 (22.8%) developed symptomatic vasospasm, which occurred in 44% and 42.4% of patients with BNI grade 4 and 5 SAH, respectively, and 26.7% of patients with Fisher grade 3 SAH (Figure). Chi-square for trend analysis demonstrated that the BNI scale (Chi-square 40.9, P < 0.0001) performed better than the Fisher scale (Chi-square 7.9, P = 0.0048) with respect to symptomatic vasospasm prediction in the combined cohort. Mean intra- and inter-observer agreement was greater for the BNI scale (kappa 0.83 and kappa 0.76, respectively) than the Fisher scale (kappa 0.62 and kappa 0.52, respectively).

    Conclusions: The present study demonstrates that the BNI scale reliably predicts symptomatic vasospasm in a large, multicenter cohort of 474 patients. The quantitative nature of the BNI scale circumvents the potential subjectivity associated with Fisher scale assessments, which may result in more reliable SAH measurements and predictions regarding symptomatic vasospasm development.

    Patient Care: The development of symptomatic vasospasm is a significant complication of aneurysmal subarachnoid hemorrhage (SAH). The original Fisher scale was proposed to identify patients at high risk for vasospasm development, so that vigilant monitoring and early interventions could potentially be undertaken. We validate a new SAH grading scale, the Barrow Neurological Institute (BNI) scale. With respect to symptomatic vasospasm, this scale has greater predictive power than the original Fisher scale and higher intra- and inter-observer reliability.

    Learning Objectives: By the conclusion of this session, participants should be able to: 1) Describe the importance of subarachnoid hemorrhage (SAH) volume/thickness on the development of symptomatic vasospasm. 2) List the gradations of the original Fisher and Barrow Neurological Institute (BNI) scales and their associated risks of symptomatic vasospasm. 3) List the shortcomings of the original Fisher scale and how the BNI scale attempts to overcome these issues.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy